NCRI 2016 | Clinical impact of APOBEC enzymes

Reuben Harris, PhD of University of Minnesota, Minneapolis, MN talks about a clinical impact of APOBEC enzymes. Breast tumor patients with low APOBEC-3B expression levels have a better prognosis than patients with high level of that enzyme, as shown in a retrospective analysis of primary tumor specimens. In addition, dr Harris talks about the analysis of ER-positive tumor samples, where primary tumor APOBEC-3B levels also predicted patient outcomes, with high levels of APOBEC-3B associated with lack of response to tamoxifen and poor outcomes. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.